Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   ProQR Therapeutics   /   WAVE LIFE SCIENCES LTD (2023) WVE

Aandeel ProQR Therapeutics NV OTC:PRQR.Q, NL0010872495

Vertraagde koers (usd) Verschil Volume
2,790   +0,110   (+4,10%) Dagrange 2,645 - 2,810 258.415   Gem. (3M) 1,6M

WAVE LIFE SCIENCES LTD (2023) WVE

Volgen
5 Posts
| Omlaag ↓
  1. forum rang 5 Piddy 10 april 2023 19:44
    info 01/2023

    The BPs are making there moves into the RNA modality.

    GSK:
    Wave Life Sciences has picked up another deal with a major pharma company.
    The Massachusetts-based biotech on Tuesday announced it has entered a strategic collaboration with GSK to advance oligonucleotide therapeutics. This includes moving along Wave’s RNA editing program that targets alpha-1 antitrypsin deficiency, dubbed WVE-006, which affects both the lungs and liver with limited treatment options.
    The deal will have a four-year research term at the beginning. It will bring together GSK’s experience in human genetics, along with its wider development and commercial abilities, with Wave’s drug discovery and development platform, called PRISM. The deal also has two elements, first a discovery collaboration, allowing GSK to potentially advance up to eight programs and Wave to advance up to three. GSK also receives the exclusive global license for WVE-006.
    Wave will get an upfront payment of $170 million, split into a $50 million equity investment and $120 million in cash. The WVE-006 program can see Wave receive up to $225 million in development and launch payments and $300 million in sales milestones.
    Once RNA editing gains POC (and I suspect GSK and Lilly already have positive clues to that effect) these stocks will pop.

    Wave continues to lead the genetic medicines field in advancing therapeutic RNA editing toward the clinic with our WVE-006 AIMer program and we expect to submit clinical trial applications for our first-in-human study in 2023. WVE-006 is distinct from other approaches in development for AATD, as it offers the opportunity to treat the root genetic cause of the disease and restore functional, wild-type protein that remains under physiological regulation. This would be a holistic solution and applicable to those with lung disease, liver disease, or both,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences. “Additionally, the opportunity for AIMers is much broader than restoring or correcting protein function in genetic diseases, as we demonstrated today with our preclinical data supporting the use of AIMers to modulate protein-protein interactions and upregulate gene expression. RNA editing is emerging as a distinct class of therapeutics with potential to address disease biology in novel and innovative ways and reach patients suffering from an array of diseases, including neurological disorders, as well as renal, cardiometabolic, or immunologic diseases. We are proud to be pioneers in this new area of genetic medicine and to have a best-in-class RNA editing capability with our AIMers.”
    ir.wavelifesciences.com/news-releases...
5 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium drie voorbeelden van IEX Premium: de exclusieve content op de site, de app op een smartphone en IEX Magazine.

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!

Word abonnee